autoimmune disease

In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
Endpoints
Eli Lilly
Merck KGaA
Btk inhibitors
autoimmune disease
evobrutinib
Flag link:
AstraZeneca spinout bags $250M, pipeline headed by late-phase autoimmune drug
AstraZeneca spinout bags $250M, pipeline headed by late-phase autoimmune drug
Fierce Biotech
AstraZeneca
autoimmune disease
Viela Bio
spinoffs
biotech
Flag link:
Here's Where Things Went Wrong for Celgene Corporation in 2017
Here's Where Things Went Wrong for Celgene Corporation in 2017
Motley Fool
Celgene
Otezla
autoimmune disease
R&D
Revlimid
Flag link:
Powerful new cancer drugs are saving lives, but can also ignite diabetes or other autoimmune conditions
Powerful new cancer drugs are saving lives, but can also ignite diabetes or other autoimmune conditions
Science
cancer
checkpoint inhibitors
autoimmune disease
type 1 diabetes
Flag link:
Merck strikes autoimmune deal with newly-emerged Cue
Merck strikes autoimmune deal with newly-emerged Cue
BioPharma Dive
Merck
autoimmune disease
Cue Biopharma
R&D
drug development
Flag link:
J&J goes back to Ionis for its second experimental pill for a GI autoimmune disease
J&J goes back to Ionis for its second experimental pill for a GI autoimmune disease
Endpoints
JNJ
Ionis Pharmaceuticals
autoimmune disease
IONIS-JBI2-2.5Rx
antisense
Flag link:
Novartis strengthens autoimmune indications for Cosentyx
Novartis strengthens autoimmune indications for Cosentyx
PM Live
Novartis
Cosentyx
autoimmune disease
psoriatic arthritis
ankylosing spondylitis
Flag link:
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Motley Fool
Big Pharma
viral hepatitis
respiratory disease
autoimmune disease
cardiovascular disease
pain
diabetes
cancer
Flag link:
Horizon CEO Tim Walbert knows patients because he is one
Horizon CEO Tim Walbert knows patients because he is one
Medical Marketing and Media
Tim Walbert
Horizon Pharma
Pharma CEOs
autoimmune disease
Duexis
patients
Flag link:
Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar
Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar
Endpoints
Eli Lilly
autoimmune disease
NKTR-358
Nektar
Flag link:
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Motley Fool
AbbVie
Humira
Upadacitinib
JAK inhibitors
autoimmune disease
Flag link:
Inside the small Norwood biotech that's making investors swoon
Inside the small Norwood biotech that's making investors swoon
Bizjournals.com
Corbus Pharmaceuticals
autoimmune disease
Flag link:
Did Biogen Just Throw in the Towel to Celgene?
Did Biogen Just Throw in the Towel to Celgene?
Motley Fool
Biogen
Celgene
MT-1303
autoimmune disease
ozanimod
Flag link:
Celgene Boldly Targeting $6 Billion (or More) in New Business
Celgene Boldly Targeting $6 Billion (or More) in New Business
Motley Fool
Celgene
Otezla
autoimmune disease
ozanimod
Mongersen
Flag link:
Biogen quietly whisks away its $544M autoimmune rival to Celgene
Biogen quietly whisks away its $544M autoimmune rival to Celgene
Endpoints
Biogen
Celgene
autoimmune disease
amiselimod
ozanimod
Flag link:
Celgene Is Building an Autoimmune Empire -- and No One Is Talking About It
Celgene Is Building an Autoimmune Empire -- and No One Is Talking About It
Motley Fool
Celgene
autoimmune disease
Otezla
ozanimod
GED-0301
Flag link:
The Most Exciting Drug in Celgene's Pipeline
The Most Exciting Drug in Celgene's Pipeline
Motley Fool
Celgene
ozanimod
autoimmune disease
Flag link:
Eisai launches research division in Massachusetts aimed at Alzheimer’s, I/O and autoimmune diseases
Eisai launches research division in Massachusetts aimed at Alzheimer’s, I/O and autoimmune diseases
Endpoints
Eisai
R&D
Massachusetts
Alzheimer's disease
autoimmune disease
Flag link:
Allergan to acquire Vitae Pharma in an all-cash deal valued at about $639 million
Allergan to acquire Vitae Pharma in an all-cash deal valued at about $639 million
Marketwatch
Allergan
Vitae
M&A
autoimmune disease
Flag link:
How AbbVie Plans To Replace Humira
How AbbVie Plans To Replace Humira
Seeking Alpha
AbbVie
Humira
R&D
autoimmune disease
ABT-122
ABT-494
ABBV-247
ALX-0061
Flag link:

Pages